Syngene International share price today

Syngene International Ltd's share price was ₹417.50 at the close on 4 November 2026. It has been falling for 89 weeks. That is 6.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹347 and ₹658, and at that close it sat 23% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Syngene International Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 11 years the share price moved +109% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: foreign funds (FIIs) cut their stake for 8 quarters in a row, indian funds and insurers (DIIs) raised their stake for 14 quarters in a row and profit down on a year earlier for 5 quarters in a row.

1. Foreign funds (FIIs) cut their stake for 8 quarters in a row

   From 20.7% to 10.1% of the company by the September 2026 quarter.

2. Indian funds and insurers (DIIs) raised their stake for 14 quarters in a row

   From 10.7% to 29.3% of the company by the September 2026 quarter.

3. Profit down on a year earlier for 5 quarters in a row

   In the September 2026 quarter profit was ₹32 crore, -52.2% on a year earlier.

   Why: Profit has fallen for five quarters, and the latest drop came because a high-margin product, Librela, was no longer in the sales mix, so fixed costs were spread over less profitable work.

   Next results: check whether the Zoetis batches are delivered on time, since that is the planned second-half rebound.

   From the earnings call on 28 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Syngene International reported revenue of ₹833 crore, down 8.6% from ₹911 crore a year earlier, and a profit of ₹32.0 crore, down 52.2% from ₹67.0 crore.

Syngene International results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Syngene International's management discussed these results on a call held on 28 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Syngene International closed at ₹417.50 on 4 November 2026, down 32.3% from ₹616.30 a year earlier (7 November 2025) and down 24.5% over five years. Its highest weekly close since March 2016 was ₹940.80 on 29 November 2024.

Syngene International share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Syngene International closed at ₹417.50, up 3.7% on the week and up 15.6% on the month. 28 Oct 2026: Syngene International held its results call for July to September 2026. Management guided: Bayview drug substance manufacturing to begin in FY28 after India process work in FY27.

Earlier

• Results for July to September 2026: Revenue down 8.6% and profit down 52.2% on a year earlier.
• 25 Jun 2026: ex-date for a dividend of ₹1.25 a share, record date 26 Jun 2026.

Syngene International paid ₹1.25 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.30% at the ₹417.50 close on 4 November 2026. The last was a dividend of ₹1.25 a share, ex-date 25 June 2026.

Syngene International dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Syngene International Ltd paid out 16% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 9 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 28 October 2026, Syngene International's management guided: Bayview drug substance manufacturing to begin in FY28 after India process work in FY27.

“We offer a dual manufacturing strategy, which many CMOs cannot do. Even Samsung does not have a facility in the US.”Siddharth Mittal, on the call for July to September 2026

What management guided

• Bayview commercial volumes only post product approval, a couple years out; first approvals planned in H2 CY28 best case.
• Biocon Park biologics batches for Zoetis to deliver in January to March 2027 back-end-loaded; no other-customer work there until next fiscal.
• Operating margin in mid-20s excluding hedge drag, guidance maintained.
• Similar hedge losses in second half on forwards for large dedicated contract, then pivot to options after expiry.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 28 October 2026.

When Syngene International reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Back-end-loaded Zoetis batches from Biocon Park facility deliver on time - confirms second-half rebound plank.

Syngene International is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Syngene International Ltd earned ₹32.0 Cr of net profit in the Sep 2026 quarter, −52.2% on the same quarter a year earlier. Full-year FY26 profit was ₹317 Cr. Over 8 years profit has grown 0.5% a year on average. That is 3.8% of the quarter's revenue. The same quarter a year earlier earned ₹67.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹317 Cr (−36.1% on the year before).

Why profit moved: revenue changed −8.6% on a year earlier and the margin moved −4.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −67.5% and revenue −6.4%. Profit is growing slower than sales: rising costs are taking part of the growth.

Syngene International Ltd reported ₹833 Cr of revenue in the Sep 2026 quarter, −8.6% on the same quarter a year earlier. Over 8 years it has grown 12.8% a year on average. The last full year, FY26, came in at ₹3,739 Cr. The last four reported quarters add to ₹3,522 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹3,739 Cr, +2.7% on the year before.

Recent pace: the last four quarters grew −6.4% on average, against 12.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −6.0%, against +1.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −60.3%, against −37.9% a year (rolling over).

Syngene International Ltd's operating margin was 18.0% in the Sep 2026 quarter, 4.0 percentage points lower than the same quarter a year ago. Across 9 years it has been between 25.0% and 33.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −4.2 percentage points on the year while gross margin changed +2.3 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 236% of Syngene International Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹915 Cr of operating cash against ₹317 Cr of profit. After ₹431 Cr of spending on assets, ₹484 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 236% of profit came in as cash: the cash cycle got 15 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building.

Syngene International Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −32 days in FY26, up from −47 days in FY21. It spent ₹2,514 Cr on assets over the last 3 years. Customers take 50 days to pay, and stock sits for 56 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹3,739 Cr, each day of that cycle ties up about ₹10.2 Cr, so roughly −₹328 Cr is tied up in the business at any time.

FY26: customers took 50 days to pay and stock sat for 56 days, about 1.8 months of sales sitting as stock, for a full cycle of −32 days, longer than FY21's −47.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 56 days. Customers pay about 50 days after that. Suppliers are paid at 138 days. Together that makes the −32-day cycle.

Spending on assets: ₹2,514 Cr over the last 3 years, against ₹1,312 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1,046 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Syngene International Ltd's P/E is 63.4×, near the high end of its own history: higher than 83% of past readings. Its usual P/E (the middle reading) is 55.0×, over 8.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹4.62.